Skip to Content
Merck
CN
  • Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis.

Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis.

Autophagy (2012-03-24)
Tiejun Zhang, Yuwen Li, Kyeong Ah Park, Hee Sun Byun, Minho Won, Juhee Jeon, Yoonjung Lee, Jeong Ho Seok, Seung-Won Choi, Sang-Hee Lee, Jin Man Kim, Ji Hoon Lee, Chang Gue Son, Zee-Won Lee, Han-Ming Shen, Gang Min Hur
ABSTRACT

Targeted disruption of STAT3 function has proven to be a useful cancer therapeutic approach by inducing apoptotic cell death. Cucurbitacin is currently under development as a small molecule of STAT3 inhibitor to trigger cell death in many cancers. Here, we systematically studied the molecular mechanisms underlying cucurbitacin-induced cell death, in particular the involvement of autophagy. Treatment with cucurbitacin resulted in non-apoptotic cell death in a caspase-independent manner. Notably, cucurbitacin enhanced excessive conversion of lipidated LC3 (LC3-II) and accumulation of autophagosomes in many cell types. Such autophagy and cell death induced by cucurbitacin were independent of its ability to inhibit STAT3 function, but mainly mediated by enhanced production of mitochondrial-derived reactive oxygen species (ROS), and subsequently activation of extracellular signal-regulated kinase (ERK) and c-jun NH2-terminal kinase (JNK). Interestingly, both the autophagy inhibitor wortmannin and knockdown of Atg5 or Beclin 1 failed to rescue the cells from cucurbitacin-induced cell death, as suppression of autophagy induced the mode of cell death to shift from autophagic cell death to caspase-dependent apoptosis. Thus the present study provides new insights into the molecular mechanisms underlying cucurbitacin-mediated cell death and supports cucurbitacin as a potential anti-cancer drug through modulating the balance between autophagic and apoptotic modes of cell death.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ATG5 (C-terminal) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody
Sigma-Aldrich
Cucurbitacin I hydrate, ≥95% (HPLC), solid
Sigma-Aldrich
Cucurbitacin B hydrate, ≥97% (HPLC)
Sigma-Aldrich
Chloroquine diphosphate salt, powder or crystals, 98.5-101.0% (EP), meets EP testing specifications
Sigma-Aldrich
3-Methyladenine, autophagy inhibitor
Sigma-Aldrich
Necrostatin-1, Necrostatin-1, CAS 4311-88-0, is a cell-permeable, potent, and selective blocker of necroptosis (EC50 = 494 nM in FADD-deficient Jurkat cells treated with TNF-α).
Sigma-Aldrich
AG 490, A cell-permeable, reversible, substrate competitive, and potent inhibitor of epidermal growth factor receptor kinase autophosphorylation (IC50 = 100 nM).
Sigma-Aldrich
SB 203580, InSolution, ≥98%, 1 mg/ml, reversible inhibitor of p38 MAP kinase
Sigma-Aldrich
Caspase Inhibitor I, Z-VAD-FMK, CAS 187389-52-2, is a cell-permeable, irreversible, pan-caspase inhibitor.
Sigma-Aldrich
Anti-Actin antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Bafilomycin A1 from Streptomyces griseus, ≥90% (HPLC)
Sigma-Aldrich
ANTI-FLAG® M2 antibody, Mouse monoclonal, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
Anti-LC3B antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
PD 98059, PD 98059, CAS 167869-21-8, is a cell-permeable, selective & reversible inhibitor of MAP Kinase Kinase (MEK). Inhibits MAP Kinase activation and subsequent phosphorylation of MAP Kinase substrates.
Sigma-Aldrich
JNK Inhibitor II, JNK Inhibitor II. SP600125, CAS 129-56-6, is a potent, cell-permeable, selective, and ATP competitive inhibitor of c-Jun N-terminal kinase (JNK; IC50 = 40 nM for JNK-1 & JNK-2 & 90 nM for JNK-3).